Treatment of depression is associated with suppression of nonspecific and antigen-specific TH1 responses in multiple sclerosis

Archives of Neurology

Volumn 58, Issue 7, 2001, Pages 1081-1086

  Mohr, David C ^a,b,c   Goodkin, Donald E ^b   Islar, Janeen ^b   Hauser, Stephen L ^b   Genain, Claude P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OKT 3; SERTRALINE;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPRESSION; FEMALE; GROUP THERAPY; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; TH1 CELL; TREATMENT OUTCOME;

EID: 0034938909     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.7.1081     Document Type: Article

References (55)

1. Revised estimate of the prevalence of multiple sclerosis in the United States
2. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis
3. Depression and multiple sclerosis
4. Depression in multiple sclerosis
5. An investigation into some psychiatric aspects of multiple sclerosis
6. Structural brain correlates of emotional disorder in multiple sclerosis
7. Depression as a major symptom of multiple sclerosis
8. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis
9. Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support
10. Multiple sclerosis
11. Disease activity and emotional state in multiple sclerosis
12. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis
13. Depression and immunity: A meta-analytic review
14. Health psychology: Psychological factors and physical disease from the perspective of human psychoneuroimmunology
15. T cells responsive to myelin basic protein in patients with multiple sclerosis
16. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides
17. Psychoimmunological dysregulation in multiple sclerosis
18. A prospective study of depression and immune dysregulation in multiple sclerosis
19. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis
20. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system
21. Interferon gamma- and interleukin 4-secreting cells in multiple sclerosis
22. Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients
23. + T cells via CD40 ligand
24. Cytokine production and serum proteins in depression
25. +, natural killer cells, and related cytokines in major depression
26. Comparative outcome trial of three treatments for depression in multiple sclerosis
27. Comparative outcomes for individual cognitive-behavioral therapy, supportive-expressive group therapy, and sertraline for the treatment of depression in multiple sclerosis
28. New diagnostic criteria for multiple sclerosis
29. Defining the clinical course of multiple sclerosis: Results of an international survey
30. Cognitive dysfunction in multiple sclerosis, I: Frequency, patterns, and prediction
31. Boston naming test: Shortened versions for use in Alzheimer's disease
32. Problem solving by patients with multiple sclerosis: Comparison of performance on the Wisconsin and California card sorting tests
33. Synaptic effects of antidepressants
34. An inventory for measuring depression
35. Autoreactivity to myelin antigens: Myelin/oligodendrocyte glycoprotein is a prevalent antoantigen
36. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
37. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and simulation of interleukin-10 secretion
38. Reactivity to myelin antigens in multiple sclerosis: Peripheral blood lymphocytes respond to predominantly to myelin oligodendrocyte glycoprotein
39. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein
40. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system
41. Identification of autoantibodies associated with myelin damage in multiple sclerosis
42. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease
43. Affective disorders in multiple sclerosis: Review and recommendations for clinical research
44. Steroid effects on central neurons and implications for psychiatric and neurological disorders
45. Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: A model for stress-related immune dysfunction
46. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production
47. Inhibition of gamma interferon synthesis by catecholamines
48. Serotonin modulates immune function in T cells from HIV-seropositive subiects
49. Inhibitory effect of vasoactive intestinal peptide on the challenge phase of allergic contact dermatitis in humans
50. The control group dilemma in clinical research: Applications for psychosocial and behavioral medicine trials
51. Treatment of depression in multiple sclerosis: Review and meta-analysis